# Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy

> **NCT05833711** · PHASE2 · UNKNOWN · sponsor: **Immunoforge Co. Ltd.** · enrollment: 39 (estimated)

## Conditions studied

- Dermatomyositis
- Polymyositis
- Idiopathic Inflammatory Myopathies

## Interventions

- **DRUG:** Froniglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05833711
- **Lead sponsor:** Immunoforge Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-05
- **Primary completion:** 2025-03
- **Final completion:** 2025-09
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05833711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05833711, "Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05833711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*